ReviewInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020
Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV.
Review in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04407507 (Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects), which is not on this map. Cited by 187 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms
Who cites it
187 citing papers in PubMed, 7 syntheses or guidelines pooled it, 480 citations in OpenAlex.
- Globally approved vaccines for COVID-19: a systematic review.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Pooled it
- Identifying COVID-19 variant through symptoms profile: Would it be possible? A rapid review.BMC infectious diseases · 2024Pooled it
- Rapid review and meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants.BMC infectious diseases · 2023Pooled it
- Pooled it
- Serial interval and incubation period of COVID-19: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.Revista Brasileira de terapia intensivaPooled it
- RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.The American journal of tropical medicine and hygiene · 2020Trial
- Advances in electrospun nanofiber-based personal protective equipment for active filtration.Discover nano · 2026Review
- Elevated IL-6 and IL-10 Levels as Prognostic Biomarkers in COVID-19 Pneumonia: A Comparative Study in Mexican Patients.Healthcare (Basel, Switzerland) · 2025Article
- Exploring the Therapeutic Potential ofJournal of microbiology and biotechnology · 2025Article
- Comparison of Platelet Indices, Lymphocyte, and Systemic Inflammation Indices on Days 1 and 8 in Surviving and Non-Surviving COVID-19 Patients at Hasan Sadikin General Hospital, Bandung, Indonesia.Journal of blood medicine · 2025Article
- Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication.EMBO reports · 2024Article
- Complexity and Diversity of the Neurological Spectrum of SARS-CoV-2 over Three Waves of COVID-19.Journal of clinical medicine · 2024Article
- Nine-Month Trend of IgG Antibody Persistence and Associated Symptoms Post-SARS-CoV-2 Infection.Healthcare (Basel, Switzerland) · 2024Article
- Spectrum of COVID-19 induced liver injury: A review report.World journal of hepatology · 2024Review
- Changes in Lymphocyte Subpopulations after Remdesivir Therapy for COVID-19: A Brief Report.International journal of molecular sciences · 2023Article
- VExD: a curated resource for human gene expression alterations following viral infection.G3 (Bethesda, Md.) · 2023Article
- The Impact of the Covid-19 Pandemic on Patients with Obsessive Compulsive Disorder (OCD).Clinical neuropsychiatry · 2023Article
- Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Review
127 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rapid spread of the coronavirus disease 2019 (COVID-19), caused by a zoonotic beta-coronavirus entitled 2019 novel coronavirus (2019-nCoV), has become a global threat. Awareness of the biological features of 2019-nCoV should be updated in time and needs to be comprehensively summarized to help optimize control measures and make therapeutic decisions.
methodsBased on recently published literature, official documents and selected up-to-date preprint studies, we reviewed the virology and origin, epidemiology, clinical manifestations, pathology and treatment of 2019-nCoV infection, in comparison with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
resultsThe genome of 2019-nCoV partially resembled SARS-CoV and MERS-CoV, and indicated a bat origin. The COVID-19 generally had a high reproductive number, a long incubation period, a short serial interval and a low case fatality rate (much higher in patients with comorbidities) than SARS and MERS. Clinical presentation and pathology of COVID-19 greatly resembled SARS and MERS, with less upper respiratory and gastrointestinal symptoms, and more exudative lesions in post-mortems. Potential treatments included remdesivir, chloroquine, tocilizumab, convalescent plasma and vaccine immunization (when possible).
conclusionThe initial experience from the current pandemic and lessons from the previous two pandemics can help improve future preparedness plans and combat disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.